|
1
|
Li Q, Wang D, Li J and Chen P:
Clinicopathological and prognostic significance of HER-2/neu and
VEGF expression in colon carcinomas. BMC Cancer. 11:2772011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Atkin WS, Edwards R, Kralj-Hans I,
Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW
and Cuzick J: UK Flexible Sigmoidoscopy Trial Investigators:
Once-only flexible sigmoidoscopy screening in prevention of
colorectal cancer: A multicentre randomised controlled trial.
Lancet. 375:1624–1633. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li MX, Liu XM, Zhang XF, Zhang JF, Wang
WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, et al: Prognostic role
of neutrophil-to-lymphocyte ratio in colorectal cancer: A
systematic review and meta-analysis. Int J Cancer. 134:2403–2413.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mathur A, Ware C, Davis L, Gazdar A, Pan
BS and Lutterbach B: FGFR2 is amplified in the NCI-H716 colorectal
cancer cell line and is required for growth and survival. PLoS One.
9:e985152014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zimonin FS: Reliable protection of chicks
against pullorum disease. Veterinariia. 8:69–70. 1973.(In Russian).
PubMed/NCBI
|
|
6
|
Maira SM, Stauffer F, Brueggen J, Furet P,
Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker
K, et al: Identification and characterization of NVP-BEZ235, a new
orally available dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor with potent in vivo antitumor
activity. Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Samuels Y, Diaz LA Jr, Schmidt-Kittler O,
et al: Mutant PIK3CA promotes cell growth and invasion of human
cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carracedo A, Ma L, Teruya-Feldstein J,
Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma
SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin
Invest. 118:3065–3074. 2008.PubMed/NCBI
|
|
9
|
Carpten JD, Faber AL, Horn C, Donoho GP,
Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage
S, et al: A transforming mutation in the pleckstrin homology domain
of AKT1 in cancer. Nature. 448:439–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Filomeni G, De Zio D and Cecconi F:
Oxidative stress and autophagy: the clash between damage and
metabolic needs. Cell Death Differ. 22:377–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenberg-Lerner A, Bialik S, Simon HU and
Kimchi A: Life and death partners: Apoptosis, autophagy and the
cross-talk between them. Cell Death Differ. 16:966–975. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Denton D, Nicolson S and Kumar S: Cell
death by autophagy: Facts and apparent artefacts. Cell Death
Differ. 19:87–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scarlatti F, Granata R, Meijer AJ and
Codogno P: Does autophagy have a license to kill mammalian cells?
Cell Death Differ. 16:12–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen HY and White E: Role of autophagy in
cancer prevention. Cancer Prev Res (Phila). 4:973–983. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murrow L and Debnath J: Autophagy as a
stress-response and quality-control mechanism: Implications for
cell injury and human disease. Annu Rev Pathol. 8:105–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Janku F, McConkey DJ, Hong DS and Kurzrock
R: Autophagy as a target for anticancer therapy. Nat Rev Clin
Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rubinsztein DC, Codogno P and Levine B:
Autophagy modulation as a potential therapeutic target for diverse
diseases. Nat Rev Drug Discov. 11:709–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ogino S and Goel A: Molecular
classification and correlates in colorectal cancer. J Mol Diagn.
10:13–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Generali D, Fox SB, Brizzi MP, Allevi G,
Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, et
al: Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular
target of rapamycin metabolic pathway by primary letrozole-based
therapy in human breast cancer. Clin Cancer Res. 14:2673–2680.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Masuda M, Shimomura M, Kobayashi K, Kojima
S and Nakatsura T: Growth inhibition by NVP-BEZ235, a dual
PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol
Rep. 26:1273–1279. 2011.PubMed/NCBI
|
|
25
|
Herrera VA, Zeindl-Eberhart E, Jung A,
Huber RM and Bergner A: The dual PI3K/mTOR inhibitor BEZ235 is
effective in lung cancer cell lines. Anticancer Res. 31:849–854.
2011.PubMed/NCBI
|
|
26
|
Mirzoeva OK, Hann B, Hom YK, Debnath J,
Aftab D, Shokat K and Korn WM: Autophagy suppression promotes
apoptotic cell death in response to inhibition of the PI3K-mTOR
pathway in pancreatic adenocarcinoma. J Mol Med Berl. 89:877–889.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Potter DS, Kelly P, Denneny O, Juvin V,
Stephens LR, Dive C and Morrow CJ: BMX acts downstream of PI3K to
promote colorectal cancer cell survival and pathway inhibition
sensitizes to the BH3 mimetic ABT-737. Neoplasia. 16:147–157. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Markman B, Dienstmann R and Tabernero J:
Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget.
1:530–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prevo R, Deutsch E, Sampson O, Diplexcito
J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S and Bernhard
EJ: Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine
inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res.
68:5915–5923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wan X, Harkavy B, Shen N, Grohar P and
Helman LJ: Rapamycin induces feedback activation of Akt signaling
through an IGF-1R-dependent mechanism. Oncogene. 26:1932–1940.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan QW, Knight ZA, Goldenberg DD, Yu W,
Mostov KE, Stokoe D, Shokat KM and Weiss WA: A dual PI3 kinase/mTOR
inhibitor reveals emergent efficacy in glioma. Cancer Cell.
9:341–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kurtz JE and Ray-Coquard I: PI3 kinase
inhibitors in the clinic: an update. Anticancer Res. 32:2463–2470.
2012.PubMed/NCBI
|
|
33
|
Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin
J, Feng GK and Zhu XF: Dual phosphoinositide 3-kinase/mammalian
target of rapamycin inhibitor NVP-BEZ235 has a therapeutic
potential and sensitizes cisplatin in nasopharyngeal carcinoma.
PLoS One. 8:e598792013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu TJ, Koul D, LaFortune T, Tiao N, Shen
RJ, Maira SM, Garcia-Echevrria C and Yung WK: NVP-BEZ235, a novel
dual phosphatidylinositol 3-kinase/mammalian target of rapamycin
inhibitor, elicits multifaceted antitumor activities in human
gliomas. Mol Cancer Ther. 8:2204–2210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brachmann SM, Hofmann I, Schnell C,
Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C and Maira SM:
Specific apoptosis induction by the dual PI3K/mTor inhibitor
NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Proc Natl Acad Sci USA. 106:22299–22304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McMillin DW, Ooi M, Delmore J, Negri J,
Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C,
Schlossman R, et al: Antimyeloma activity of the orally
bioavailable dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor NVP-BEZ235. Cancer Res. 69:5835–5842. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujiwara K, Iwado E, Mills GB, Sawaya R,
Kondo S and Kondo Y: Akt inhibitor shows anticancer and
radiosensitizing effects in malignant glioma cells by inducing
autophagy. Int J Oncol. 31:753–760. 2007.PubMed/NCBI
|
|
38
|
Yang S, Xiao X, Meng X and Leslie KK: A
mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
PLoS One. 6:e263432011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang Y, Xing D, Zhou F and Chen Q:
Mitochondrial autophagy protects against heat shock-induced
apoptosis through reducing cytosolic cytochrome c release and
downstream caspase-3 activation. Biochem Biophys Res Commun.
395:190–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu CX, Zhao L, Yue P, Fang G, Tao H,
Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Augmentation of
NVP-BEZ235′s anticancer activity against human lung cancer cells by
blockage of autophagy. Cancer Biol Ther. 12:549–555. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cerniglia GJ, Karar J, Tyagi S,
Christofidou-Solomidou M, Rengan R, Koumenis C and Maity A:
Inhibition of autophagy as a strategy to augment radiosensitization
by the dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor NVP-BEZ235. Mol Pharmacol. 82:1230–1240. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ghadimi MP, Lopez G, Torres KE, Belousov
R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, et al:
Targeting the PI3K/mTOR axis, alone and in combination with
autophagy blockade, for the treatment of malignant peripheral nerve
sheath tumors. Mol Cancer Ther. 11:1758–1769. 2012. View Article : Google Scholar : PubMed/NCBI
|
